Corporate Presentation

PDS Overview - March 2019

Corporate Profile

PDS Biotechnology has a growing pipeline of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, cervical cancer, anal cancer, prostate cancer, breast cancer and other cancers. PDS Biotechnology’s lead product candidate PDS0101 demonstrated strong induction of the expected immune responses (e.g. antigen-specific CD8+ T-cell responses) without any observed dose-limiting toxicities in a completed Phase 1/2a clinical trial.

Stock Information

PDSB (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Change (%) Stock is Down 0.06 (0.90%)
Data as of May 21, 2019 11:25 a.m. ET
Refresh quote

IR Contact


More >>

Latest News

May 15, 2019 - PDS Biotechnology Announces Publication Supporting Novel Mechanisms of Action of its Proprietary Versamune® Platform in Cancer Immunotherapy
Read More
May 14, 2019 - PDS Biotechnology Reports First Quarter 2019 Financial Results and Provides Business Update
Read More
April 8, 2019 - PDS Biotechnology Appoints Stephen Glover to its Board of Directors
Read More

More >>

Data provided by Nasdaq. Minimum 15 minutes delayed.

Printer Friendly Version Print PageE-mail this page Email PageRSS RSS FeedsE-mail Alerts Email AlertsView contacts IR Contacts